SOUTH SAN FRANCISCO, Calif.,
June 1, 2017 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
Ryan Maynard, the company's chief
financial officer, is scheduled to present a company overview at
the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017 at 11:30am EDT.
To access the live webcast of the presentation or the subsequent
archived recording, log on to www.rigel.com. Please connect to
Rigel's website several minutes prior to the start of the live
webcast to ensure adequate time for any software download that may
be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a clinical-stage biotechnology company dedicated to the
discovery and development of novel, targeted drugs in the
therapeutic areas of immunology, oncology and immuno-oncology.
Rigel's pioneering research focuses on signaling pathways that are
critical to disease mechanisms. The company's current clinical
programs include clinical trials of fostamatinib, an oral spleen
tyrosine kinase (SYK) inhibitor in a number of indications. The
company submitted an NDA to the FDA for fostamatinib in patients
with chronic or persistent immune thrombocytopenia (ITP) in
April 2017. Rigel is also conducting
Phase 2 clinical studies with fostamatinib in IgA nephropathy
(IgAN) and autoimmune hemolytic anemia (AIHA). In addition, Rigel
has product candidates in development with partners BerGenBio AS,
Daiichi Sankyo and Aclaris Therapeutics.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
Media Contact: Susan C. Rogers,
Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2017-global-healthcare-conference-300466864.html
SOURCE Rigel Pharmaceuticals, Inc.